Association of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study
Open Access
Abstract
Background and Objectives: Sodium–glucose cotransporter 2 (SGLT2) inhibitors increase urinary glucose excretion, but the relationship between glycosuria and findings supporting urinary tract infection (UTI) remains unclear. We evaluated associations of SGLT2 inhibitor use with glycosuria, pyuria, UTI-compatible symptoms, and significant urine culture positivity in adults with type 2 diabetes. Materials and Methods: This prospective cross-sectional study included 251 adults who reported using every agent in their current oral antidiabetic regimen for at least three months. Blood tests, urinalysis, and midstream urine culture were obtained at a single study visit. SGLT2 inhibitor users and nonusers were compared; contaminated cultures were excluded from culture-based analyses. Multivariable logistic regression examined factors associated with glycosuria and pyuria. Results: Overall, 108 participants (43.0%) used an SGLT2 inhibitor (dapagliflozin, n = 51; empagliflozin, n = 57). Glycosuria was more frequent among users than nonusers (69.4% vs. 39.9%; OR = 3.43; 95% CI, 2.02–5.82; p < 0.001). In multivariable analysis, SGLT2 inhibitor use (adjusted OR = 3.14; 95% CI, 1.75–5.63) and each 1% increase in HbA1c (adjusted OR = 1.56; 95% CI, 1.27–1.92) were independently associated with glycosuria. Pyuria and UTI-compatible symptoms did not differ between groups. Among 217 evaluable cultures, significant culture positivity was numerically higher among users, but the estimate was imprecise (9.5% vs. 4.1%; OR = 2.45; 95% CI, 0.79–7.57; p = 0.110). Symptomatic culture positivity was similar (4.2% vs. 4.1%; p = 1.000). Conclusions: SGLT2 inhibitor use and higher HbA1c levels were independently associated with glycosuria. The small number of culture-positive events precludes firm conclusions about culture-based outcomes; these analyses are exploratory and do not demonstrate the presence or absence of an association. Glycosuria alone should not be interpreted as an indicator of UTI.Keywords
This publication has 21 references indexed in Scilit:
- Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims DatabaseDiabetes Therapy, 2024
- A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus studyThe Lancet Infectious Diseases, 2024
- Asymptomatic pyuria and bacteriuria are not risk factors for urinary tract infection in women with type 2 diabetes mellitus initiated SGLT2 inhibitorsInternational Urology and Nephrology, 2023
- Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score–matched Population-based Cohort StudyCanadian Journal of Diabetes, 2022
- Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitusJournal of Diabetes Investigation, 2020
- Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2019
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trialsActa Diabetologica, 2018
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysisScientific Reports, 2017
- Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuriaDiabetes Research and Clinical Practice, 2014
- Pathogenesis of bacteriuria in women with diabetes mellitusInternational Journal of Antimicrobial Agents, 2002